Ischaemia without obstructive coronary artery disease: the pathophysiology of microvascular dysfunction.


Journal

Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 28 8 2020
medline: 8 1 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

Nearly one-third of patients presenting with angina have unobstructed epicardial coronary arteries and evidence of coronary microvascular disease. Up until recently, the pathophysiology of coronary microvascular disease has been poorly understood, resulting in limited effective therapeutic options in these patients. As a result, patients with coronary microvascular disease continue to suffer from a poor quality of life and adverse cardiovascular outcomes. Recent mechanistic studies have improved our understanding of the pathophysiology underlying coronary microvascular dysfunction; these studies have implicated the nitric oxide and endothelin pathways as the main drivers. The aim of this article is to review our current understanding of the pathophysiology of ischaemia in patients with coronary microvascular disease. Patients with angina who have coronary microvascular disease, but no obstructive coronary artery disease, are unable to augment their coronary blood flow in response to physiological stress, thereby predisposing them to myocardial ischaemia as a result of supply:demand mismatch in the myocardium. In addition to abnormalities of vascular resistance, perturbations in cardiac-coronary coupling also contribute to ischaemia in these patients. Although impaired flow reserve is the diagnostic hallmark, mechanistic studies have demonstrated that the underlying pathophysiology is heterogeneous. At present, two main endotypes have been identified, which can be readily differentiated on the basis of minimal microvascular resistance. A better understanding of the pathophysiology and mechanisms driving ischaemia in coronary microvascular dysfunction may stimulate the development of individualised therapies that may lead to an improvement in patients' quality of life and prognosis.

Identifiants

pubmed: 32852345
doi: 10.1097/HCO.0000000000000788
pii: 00001573-202011000-00017
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

720-725

Subventions

Organisme : British Heart Foundation
ID : FS/16/49/32320
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T029390/1
Pays : United Kingdom

Références

Finegold J, Asaria P, Francis D. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 2013; 168:934–945.
Sara J, Widmer R, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. J Am Coll Cardiol Intv 2015; 8:1445–1453.
Tavella R, Cutri N, Tucker G, et al. Natural history of patients with insignificant coronary artery disease. Eur Heart J Qual Care Clin Outcomes 2016; 2:117–124.
AlBadri A, Bairey Merz C, Johnson B, et al. Impact of abnormal coronary reactivity on long-term clinical outcomes in women. J Am Coll Cardiol 2019; 73:684–693.
Pepine C, Anderson R, Sharaf B, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia: results from the national heart, lung and blood institute. WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010; 55:2825–2832.
Duncker D, Koller A, Merkus D, Canty J Jr. Regulation of coronary blood flow in health and ischemic heart disease. Prog Cardiovasc Dis 2015; 57:409–422.
Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation 2019; 140:1805–1816.
Liu A, Wijesurendra RS, Liu JM, et al. Diagnosis of microvascular angina using cardiac magnetic resonance. J Am Coll Cardiol 2018; 71:969–979.
Perera D. Cardiac-coronary coupling. J Am Coll Cardiol 2016; 68:1661–1663.
Lumley M, Williams R, Asrress KN, et al. Coronary physiology during exercise and vasodilation in the healthy heart and in severe aortic stenosis. J Am Coll Cardiol 2016; 68:688–697.
Rahman H, Demir OM, Khan F, et al. Physiological stratification of patients with angina due to coronary microvascular dysfunction. J Am Coll Cardiol 2020; 75:2538–2549.
van de Wouw J, Sorop O, van Drie R, et al. Perturbations in myocardial perfusion and oxygen balance in swine with multiple risk factors: a novel model of ischemia and no obstructive coronary artery disease. Basic Res Cardiol 2020; 115:21.
Seddon M, Melikian N, Dworakowski R, et al. Effects of neuronal nitric oxide synthase (nNOS) on human coronary diameter and blood flow in vivo. Circulation 2009; 119:2656–2662.
Shabeeh H, Melikian N, Dworakowski R, et al. Differential role of endothelial versus neuronal nitric oxide synthase in the regulation of coronary blood flow during pacing-induced increases in cardiac workload. Am J Physiol Heart Circ Physiol 2013; 304:H1277–H1282.
Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction [published online ahead of print, 2020 Jan 23]. Eur Heart J 2020; ehz915doi:10.1093/eurheartj/ehz915.
doi: 10.1093/eurheartj/ehz915
Sezer M, Kocaaga M, Aslanger E, et al. Bimodal pattern of coronary microvascular involvement in diabetes mellitus. J Am Heart Assoc 2016; 5:e003995.

Auteurs

Aish Sinha (A)

The BHF Centre of Excellence and the NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH